Semaglutide Shows Early Heart Benefits: SELECT Trial Results
Semaglutide’s rapid Impact on Heart Health: New Insights from SELECT Trial Semaglutide, a medication initially developed for type 2 diabetes, is showing promise in rapidly reducing the risk of heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes. This is according to a … Read more